Better Health for All

Collegium Pharmaceutical's core product, Xtampza ER, is an opioid, a highly addictive substance.

The company faced allegations of misleading marketing regarding its risks and appropriate uses, claiming it was a "responsible alternative" despite having the same active ingredient (oxycodone) as other opioids. This led to settlements totaling $2.75 million with 27 U.S. cities, counties, and subdivisions, and $185,000 with the Massachusetts state government, related to the opioid crisis. These actions indicate a severe negative health impact from its principal goods and services, and a systematic concealment of known health risks through misleading marketing. The company's alleged role in the opioid crisis represents major health-harming externalities with inadequate remediation, and an inadequate response to a public health emergency by prioritizing profit through misleading marketing. Furthermore, the alleged misleading marketing to healthcare professionals constitutes deliberate misinformation undermining health literacy. The company's alleged role in the opioid crisis and misleading marketing of an opioid product also indicates insufficient addiction controls despite high-risk products.

Fair Money & Economic Opportunity

Collegium Pharmaceutical, Inc. is a pharmaceutical company.

Its core business activities do not involve lending, deposit services, or other financial products that would directly impact the KPIs for 'Fair Money & Economic Opportunity'. The rubric explicitly states a score of 0 for KPIs when the firm does not offer lending or deposit services, has no APR or fee structures to evaluate, no revenue from high-cost financial products, no dedicated inclusion programs in finance, no customer finance data, is not regulated as a lender, or has no direct impact on customer credit or savings outcomes. Therefore, all KPIs are scored as 0, indicating 'Not applicable' as per the rubric's definitions for companies outside the financial services sector.

Fair Pay & Worker Respect

For the 2024 fiscal year, Collegium Pharmaceutical reported a CEO-to-median employee pay ratio of 54:1.

The company achieved an employee engagement score of 88% in its 2024 ESG Report, which was 20% above the Pharma Benchmark.

Fair Trade & Ethical Sourcing

No specific quantitative data is available across the provided articles regarding fair trade certifications, supply chain audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clauses in supplier contracts, materials risk, or supplier diversity spend.

The company emphasizes an unwavering commitment to the highest ethical standards and corporate social responsibility, and publishes an ESG report. Collegium Pharmaceutical also supports STEM education through partnerships and a scholarship program, which launched in 2023 and awards two full-ride scholarships annually.

Kind to Animals

No specific, concrete evidence was found in the provided articles regarding Collegium Pharmaceutical, Inc.'s performance across any of the 'Kind to Animals' KPIs. explicitly states that information for all KPIs is unknown.

details actions and plans by the FDA, not by Collegium Pharmaceutical, Inc. mentions 'Significant Involvement' in animal testing for COLL but provides no quantitative data or specific details that can be mapped to any of the defined KPI tiers. Therefore, all KPIs have been omitted due to a lack of direct, measurable evidence for the company.

Planet-Friendly Business

In 2023, the company's total carbon emissions were 5,670 metric tons CO2e.

The company incurred $1.2 million in environmental compliance costs in 2023 and invested $450,000 in EPA regulatory compliance during the same year. No major environmental compliance violations were recorded.

Respect for Cultures & Communities

Collegium Pharmaceutical, Inc. has no reported cultural appropriation incidents.

The company's operations do not appear to involve indigenous communities, cultural sites, or contexts that would necessitate specific cultural impact assessment protocols or FPIC processes. Therefore, these KPIs are considered not applicable to its business model. Collegium awards two full-ride scholarships each year through the Collegium Pharmaceutical Scholarship Program, launched in 2023, to Massachusetts-based high school seniors. This represents a distribution of non-core revenue to community development funds, but the percentage is not specified. Based on the number of scholarships, it falls into the 1-3% tier for community fund allocation.

Safe & Smart Tech

The company states that information collected is limited to what is necessary, and users can request removal from its database.

Collegium Pharmaceutical maintains a website privacy policy and complies with CCPA, cGMPs, FDA, DEA, and other applicable regulations. The company utilizes the NIST cybersecurity framework, implements company-wide policies, operating procedures, periodic testing, systems monitoring, patch management, and mandatory ongoing employee training. Third-party penetration tests are conducted, and SOC 1 reports for third-party vendors are reviewed annually. The Audit Committee receives quarterly cybersecurity updates from the Head of Information Technology, who has over 20 years of experience. The company has experienced security incidents related to its data and systems or those of its vendors, but no specific details on frequency, scale, or impact are provided.